ACS is an umbrella term encompassing ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable angina. Current drug targets for ACS, particularly those in the acute setting, include the molecular components of platelet aggregation, coagulation, and fibrinolysis. Posthospital management of ACS is targeted at reducing the incidence of recurrent thrombotic events, preventing adverse cardiac remodeling, and prolonging survival. Here we show how ACS is currently being treated and what drives the choice of pharmacotherapy for ACS patients in both the acute hospital and the 12-month posthospital settings, from the initiation of therapy, through to further lines of treatment.
Markets covered: United States
Methodology: Survey of 51 interventional and 49 non-interventional cardiologists in the United States, completed in January 2018.
Indication coverage: acute coronary syndrome
Key drugs covered: Brilinta, Effient, Zontivity, clopidogrel, Praluent, Repatha, bivalirudin, heparins, GP IIb/IIIa antagonists, ACE inhibitors, ARBs, beta blockers, and statins.
Key companies mentioned: AstraZeneca, Amgen, Sanofi, Regeneron, Eli Lilly, Chiesi, The Medicines Company, Roche, Janssen, Merck, and Medicure.